Pomerantz LLP is investigating claims on behalf of Valneva SE investors following the company's announcement that its Lyme disease vaccine failed to meet the primary endpoint in a Phase 3 trial. Despite the data being called positive, the low incidence of disease cases led to a 37% drop in Valneva's ADR price. The investigation focuses on whether Valneva and its executives engaged in securities fraud or other unlawful practices. Investors affected are encouraged to contact the law firm for potential class action participation.
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
